Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$65.68 USD

65.68
3,456,884

-1.42 (-2.12%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Varian (VAR) Earnings and Revenues Miss Estimates in Q1

Varian (VAR) gains from core Oncology segment in fiscal Q1.

Align Technology (ALGN) Earnings Beat in Q4, Margins Rise

We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies during Q4.

Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?

Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.

Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates

Stryker's (SYK) fourth-quarter earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.

What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?

Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.

Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall

Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.

PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates

PerkinElmer's (PKI) Q4 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.

Here's Why You Should Add HealthEquity (HQY) to Portfolio Now

Solid prospects in the HSA industry consistently drive HealthEquity (HQY).

DexCom (DXCM) Gains As Market Dips: What You Should Know

DexCom (DXCM) closed at $235.45 in the latest trading session, marking a +0.65% move from the prior day.

Hill-Rom's (HRC) Q1 Earnings Top Estimates, Revenues In Line

Sales in Hill-Rom's (HRC) Surgical Solutions suffer a massive setback, thanks to the divestiture of surgical consumables.

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.

Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?

Is (DXCM) Outperforming Other Medical Stocks This Year?

Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?

Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.

What's in Store for AmerisourceBergen (ABC) in Q1 Earnings?

AmerisourceBergen's (ABC) Q1 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.

Intuitive Surgical (ISRG) Q4 Earnings Top, Margins Expand

Intuitive Surgical (ISRG) gains from solid international show in Q4.

NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3

NextGen (NXGN) gains from Recurring revenues in Q3, bookings down.

Neena Mishra headshot

Best Thematic ETFs for 2020: Cloud, Internet of Things & More

Find out more about cloud computing, Internet of Things, video games and infrastructure ETFs.

Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?

Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.

Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.

What's in Store for Varian Medical (VAR) in Q1 Earnings?

Demand for Eclipse and TrueBeam is expected to have driven Varian's (VAR) Oncology revenues in fiscal Q1.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

DexCom (DXCM) expects its strong product portfolio to consistently drive top line.

Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now

Veeva (VEEV) sees a slew of positive developments.